As monoclonal antibodies that target vascular endothelial growth factor (VEGF) (e.g. Bevacizumab) and epidermal growth factor receptor (EGFR) (e.g. Cetuximab or Panitumumab) have shown benefit in patients with metastatic colorectal cancer [54]–[56], a future area of interest would be to evaluate TTS combination therapies with these more established treatments. The gene discussed is EGFR; the disease is metastatic colorectal cancer.